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Abstract: Not applicable according to the HYPERTENSION format for the present  “Brief 
Review” manuscript format. 
 
 
 
Key words:  atherosclerosis, biobanks, cardiovascular disease, harmonization, hypertension 
pregnancy, preeclampsia, placenta.  
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 3
1. Background: Why we need to better understand the associations between pregnancy and 
future cardiovascular health 
  
In 2011, the American Heart Association added preeclampsia, gestational diabetes and delivery of a 
growth-restricted child as pregnancy-related risk factors for cardiovascular disease (CVD).1 This 
move was applauded by the obstetric research community which for some years had emphasized the 
importance of pregnancy as a “stress test” for detecting women at excessive risk for premature 
CVD.2-4 
CVD is the leading cause of death for men and women in high income and most low to middle 
income countries.5 Globally, coronary artery disease kills more women than men6 although women 
develop CVD 10-15 years later than men. Women frequently present with unrecognized CVD 
symptoms and are twice as likely as men to die of a first acute myocardial infarction if less than 50 
years old.7 The preclinical stages of CVD are evident from a young age and are modifiable through 
control of classic risk factors (insulin resistance/diabetes mellitus, obesity, lack of exercise, tobacco 
smoking, hypertension and hyperlipidemia).8,9 In this regard pregnancy is a window of opportunity 
for identifying those women with perinatal complications who may benefit from early risk detection 
and early CVD prevention.  
In this paper we summarize the associations between pregnancy, placenta-related pregnancy 
complications, and future maternal cardiovascular disease. We present established as well as more 
novel hypotheses, which may explain these epidemiological associations.  The interventions that 
potentially could reduce risks of future cardiovascular disease are enumerated. To facilitate progress 
we suggest methods of harmonizing study designs, long-term follow-ups of pregnancy cohorts and 
biobanks, and pooling of the world’s data in ways that can enhance the power of current and future 
research. 
 
2.  Associations between pregnancy complications and future CVD risk 
 2.1  Preeclampsia and fetal growth restriction and future CVD risk 
    Preeclampsia is a pregnancy specific multisystem disorder defined by new-onset hypertension 
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and proteinuria after gestational week 20, or new onset preeclampsia-associated signs in the absence 
of proteinuria.8 Preeclampsia requires the presence of a placenta or residual placental components 
(postpartum preeclampsia), but the relative contributions of maternal predisposing factors versus 
placental factors to its  pathophysiology are not well delineated.9 Women with essential 
hypertension, obesity, pregestational diabetes mellitus and renal disease are at elevated risk for 
developing preeclampsia. Several large population based studies demonstrate that women who have 
had preeclampsia are at increased risk for later CVD and premature death compared to women with 
healthy pregnancies.10-14 Women who have experienced either preeclampsia or fetal growth 
restriction have a two-fold increased risk compared to pregnancies with a normal outcome. When a 
woman has both preeclampsia and fetal growth restriction the likelihood of cardiovascular disease 
may be as much as 8-fold higher.15;16 Recurrent,12;14;17 more severe, and early-onset preeclampsia, 
as well as preeclampsia with concurrent neonatal morbidity increase the risk of later life 
CVD,14;16;18;19 much more than gestational hypertension (without proteinuria or other preeclampsia-
associated features) or late-onset preeclampsia.13;20-22  
2.2 Prematurity, miscarriage and future CVD risk  
Women with a history of preterm birth (<37weeks gestation), even without pregnancy-
induced hypertension23 or preeclampsia,10;11;24 are twice as likely to die from CVD compared to 
women who delivered a  term. Spontaneous preterm labor is caused by multiple pathologic 
processes;25 nonetheless, delivery of a preterm or small for gestational age infant overall, 
independent of smoking and other risk factors, has been shown to increase the risk of CVD death 
and hospitalization later in life.26 Although less frequently investigated, recurrent miscarriages have 
also been linked to future CVD27 and to endothelial dysfunction.28 Additionally, recurrent 
pregnancy loss is associated with pregnancy complications such as placental abruption and 
hypertensive pregnancy disorders, which are independently associated with markers of 
cardiovascular dysfunction, at least in the short-term.29;30 
     2.3 Diabetes mellitus in pregnancy and future CVD risk 
Fo
r H
yp
ert
en
sio
n P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De
str
oy
 af
ter
 us
e.
HYPE201506357-R1 
 
 5
 Women who develop gestational diabetes have a 70% higher risk for future CVD than those 
with no history of the disorder, mostly attributed to an increased risk for developing type 2 
diabetes.31 As many as half of women with a pregnancy complicated by gestational diabetes 
mellitus develop type 2 diabetes within 5 years,32 and the diabetes risk is reported as seven-fold as 
compared to normoglycemic pregnancies.33 Whether pregnancy per se exacerbates the increased 
risk for later life CVD associated with pre-existing diabetes is not known. Women with type 1 
diabetes seem, however, to be more at risk for developing retinopathy and nephropathy later in life 
if they suffered from preeclampsia.34 Chronic kidney disease is considered an independent CVD 
risk factor35 and nephropathy may therefore add to the overall CVD risk after a preeclamptic 
pregnancy in women with pregestational diabetes. 
 
3. Normal pregnancy and future risk for CVD 
Several studies report an association between the number of a woman’s pregnancies, even without 
adverse outcomes, and maternal CVD risk,36-40 whereas others fail to find such an association.41;42 
High number of children does not elevate CVD risk in men.43 In a large Swedish population based 
registry study, parity was independently associated with future maternal CVD in a J-shaped fashion 
(where 2 births represented the lowest risk) following adjustment for socioeconomic factors and 
pregnancy-related complications. The highest risk was amongst women with more than 5 births.40 
The same J-shaped trend between number of births and maternal cardiovascular mortality was 
found in a recent study from the Norwegian Birth Registry, but only in women with less than 10 
years of education.44 The number of offspring does not seem to increase the CVD risk for the male 
partners, after correcting for obesity and metabolic risks,38 suggesting a pathophysiologic effect 
from pregnancy, but this finding requires replication. Nulliparity per se has been associated with 
increased CVD risk,40 but also subfertile women who eventually conceive and have a child are at 
increased risk for CVD, even after adjusting for CVD risk factors and adverse pregnancy outcomes, 
suggesting shared risk factors for CVD and infertility.45 
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 Women who deliver either large or small birthweight for gestational age (LGA and SGA) 
infants have been identified as being at increased risk for future CVD.46 However study results are 
inconsistent,46 and the association may be influenced by the population prevalence of gestational 
and pregestational diabetes mellitus as these conditions lead to LGA babies. The association of both 
LGA and SGA with preeclampsia47 further confounds the birthweight and CVD relationship. 
Perhaps because placental weight and newborn weight are highly correlated, low placental weight 
also appears to increase maternal risk for future CVD.48 The impact of breast-feeding on long-term 
maternal CVD seems also to be protective.49  
  
4. Pregnancy: mechanistic associations to future CVD 
During pregnancy the maternal cardiovascular system undergoes substantial physiological adaptive 
changes,50 which may also differ according to fetal gender and pregnancy outcome.51 Repetitive 
cardiac stress could underlie a report of an association between the number of live births with a 
small, but significant, increase in left ventricular mass and a small reduction in left ventricular 
ejection fraction from middle age.52 In addition the metabolic consequences of uncomplicated 
pregnancies could be potentially atherogenic,53 which could be exaggerated in those with pre-
existing dyslipidemia, for example in obese women or diabetics. 
 4.1 Preeclampsia/ placental dysfunction and mechanisms for increased maternal CVD 
risk  
The most widely held hypothesis to explain the link between preeclampsia and CVD focuses 
on common risk factors.54 Preeclampsia and CVD may share common genetic risk factors,55;56 
although specific genetic origins of preeclampsia and placental dysfunction remain ill defined. Both 
preeclampsia57 and atherosclerosis58;59 arise from vascular inflammation with its associated 
endothelial dysfunction. Common risks include obesity, diabetes mellitus, insulin resistance and 
hyperglycemia, dyslipidemia (including hypertriglyceridemia and small, dense LDL-particles),60-64 
hypertension, a family history of CVD,65 and the metabolic syndrome.18;66 Paradoxically, cigarette 
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smoking, which augments the risk for atherosclerosis and CVD, reduces the risk for preeclampsia in 
women who smoke in middle and late pregnancy.67 The latter may be mediated by a modulatory 
effect of carbon monoxide on placental production of angiogenic and antiangiogenic factors.68 The 
“antiangiogenic factor” sFlt1 (soluble fms-like tyrosine kinase 1; reviewed below as an important 
biomarker for early-onset preeclampsia) is lower in smokers than non-smokers during pregnancy.69  
An alternative hypothesis suggests that pregnancy in general, and preeclampsia (and other 
placental disorders) in particular, worsen preexisting, subclinical CVD risk factors or even induce 
de novo risk as reviewed above. A large Norwegian population based study, whilst proposing that 
pre-pregnancy risk factors are more important, 70-72 also showed that most CVD risk factors 
remained significantly higher after preeclampsia following adjustment for pre-pregnancy values. 
Possibly, the dyslipidemia of preeclampsia could accelerate progression toward clinical and more 
advanced atherosclerotic lesions and hypertension.73;74  
It is possible that products of the dysfunctional placenta in preeclampsia could permanently 
compromise the maternal cardiovasculature.74;75 These could include inflammatory molecules in 
general as well as factors that perturb maternal ‘angiogenic balance’: increased circulating sFlt1 and 
sEng (soluble endoglin), and reduced placental growth factor (PlGF) as well as unmeasurable low 
levels of free VEGF (vascular endothelial growth factor) during pregnancy.76 Although sFlt1 falls 
rapidly after delivery, a modest dysregulation several months and years after a preeclamptic 
pregnancy has been described.77,78;79 Increased angiotensin II sensitivity and sFlt-1 response to 
angiotensin II infusion in women with previous preeclampsia has been reported, supporting lasting 
dysfunctional angiogenic responses.80 Interestingly, agonistic autoantibodies against the angiotensin 
II type 1 receptor are present in many preeclamptic pregnancies, and may also persist postpartum in 
some cases and seem to correlate with dysregulated angiogenic biomarkers,81suggesting another 
potential molecular link between pregnancy and future CVD that merits further research. Studies 
prior to conception are needed to determine whether these pregnancy and postpartum findings 
reflect a pre-existing profile and/or placental dysfunction. Of relevance, a precipitating role for 
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preeclampsia per se has been implicated in the study of the serum proteome of an experimental 
mouse model in which preeclampsia was induced by adenovirus delivery of sFlt1. At 6 months 
postpartum, increased expressions of proteins related to CVD were found in comparison to the 
postpartum profile of normally pregnant mice.82  
Stem cells, either maternal mesenchymal stem cells or endothelial progenitor cells (EPC), 
offer intriguing potential as mediators of persistent cardiovascular dysregulation caused by a 
dysfunctional placenta. Circulating EPC are reportedly reduced in preeclampsia,83 but pre-
pregnancy studies of EPC are lacking. EPC, markers of endothelial health, are similarly reduced in 
patients with essential hypertension, in whom EPC senescence is accelerate . It is possible, 
although not established, that the extremely low free VEGF concentrations associated with any 
pregnancy, and possibly even lower in early-onset preeclampsia or fetal growth restriction, could 
reduce EPCs. Both VEGF and PlGF increase EPC recruitment, mobilization and survival outside of 
pregnancy.84;85 A reduction in EPC in pregnancy, such as observed in preeclampsia, could 
potentially affect long-term endothelial function.  
The influence of pregnancy on the maternal heart,52 and effects of preeclamptic pregnancies 
in particular, have recently been strongly implicated in long-term cardiovascular risk.86 80% of 
women with preeclampsia show an “adaptive response” to the increased afterload of preeclampsia 
by left ventricular remodeling. One year postpartum, even in the absence of hypertension, one third 
of previously preeclamptic women presented global diastolic and regional longitudinal systolic 
dysfunction with septal bulging, indicative of myocardial damage, possibly as a consequence of 
ischemia or fibrosis. These changes were more severe and more frequent when associated with 
preterm, rather than term preeclampsia.86 The long-term CVD outcome remains unknown, 75 but as 
diastolic dysfunction is recognized to predate heart failure and increased mortality,87;88 poor long-
term cardiovascular health is likely.  
 
5. The important research questions 
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One of the most important questions is: does pregnancy cause or reveal an increased risk for CVD 
problems? The primary issues are of pre-pregnancy predisposition, the effect of pregnancy itself, 
and exaggeration of risk by pregnancy complications. These can only be resolved by new, and 
necessarily expensive prospective longitudinal cohort studies of women pre- and post- pregnancy. 
Medical management will be much better targeted and evidence-based once these issues have been 
clarified. 
5.1 Optimal long-term medical supervision of women after pregnancies associated with 
increased CVD risk 
In general, it is recommended that following pregnancy, women with pre-existing renal or 
cardiac complications or suffering from diabetes mellitus, should be offered appropriate specialist 
follow-up to assess CVD risk and reduce ultimate CVD morbidity. The advice for clinical follow-
up of an otherwise healthy woman following complication in pregnancy associated with higher 
CVD risk is however fragmentary, and there is no global consensus (Supplemental Table 1). 
Furthermore many of the recommendations recognize the inadequacy of informative data,89 and in 
the case of the American College of Obstetricians and Gynecologists (ACOG), the 
recommendations are presented only as suggestions.8 For women with gestational diabetes mellitus 
(GDM), several guidelines (Supplemental Table 1) recommend routine oral glucose tolerance 
testing postpartum, or measurements of fasting glucose and HbA1c.32 Adherence to these 
postpartum recommendations is generally unknown, and long-term follow-up recommendations 
after GDM are lacking in most guidelines. Currently there are no recommendations for maternal 
follow-up after premature delivery, fetal growth restriction, SGA or recurrent pregnancy loss in 
relation to future CVD. 
A much better understanding of the natural history and time-course of progression towards 
cardiovascular disease after at-risk pregnancies is needed if evidence-based strategies for follow-up 
are to be more widely adopted. Demonstration of cost benefit is essential to convince policy makers 
and payers. We also need to know if early intervention would be more effective than current ad hoc 
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and unsystematic follow-up. An established risk score for CVD, the Framingham score, calculates 
the 10-year gender-specific risk for cardiovascular events. A young population is in general unlikely 
to suffer from CVD in the next 10 years. Framingham risk score is therefore very low for young 
women, even for those with classical and gender-independent risk factors for CVD such as diabetes 
and obesity.90 This present risk score therefore seems inapplicable for young women, especially 
since the CVD risk associated with pregnancy disorders is not included. Indeed, the American Heart 
Association emphasizes that a low Framingham risk score is not sufficiently exclusive of risk for 
CVD in young women,91 and have implemented lifestyle advice independent of this scoring system 
for women whose pregnancies were complicated by preeclampsia, fetal growth restriction, 
gestational diabetes or a premature delivery (Supplemental Table 1). 
5.2 Pregnancy biomarkers and improved risk stratification for CVD and targeted 
intervention 
      Preeclampsia and preterm birth are associated with increased insulin resistance, dyslipidemia 
and inflammatory activation all relevant in the nonpregnant setting to cardiovascular disease.  It is 
possible that the degree of abnormality could be relevant to later life CVD. Specific to pregnancy, 
maternal circulating angiogenic and antiangiogenic biomarkers are dysregulated in placenta-related 
pregnancy disorders.77 Elevated circulating sFlt1 and low PlGF in pregnancy may have potential as 
predictors also of long-term CVD many years after pregnancy; a high sFlt1: PLGF ratio might 
direct postpartum interventions to those with greatest need. This hypothesis is readily testable in 
cohorts with postpartum clinical cardiovascular follow-up data.  
 Outside pregnancy, a high circulating PlGF (assumed to be endothelial-derived) is related to 
an increase in CVD events, but has only been investigated in elderly women with a previous CVD 
event.92 There is little data on the associations between pregnancy and postpartum sFlt1and/or PlGF 
levels and not known if they play a role as potential biomarkers of future CVD risk. A continuing 
search for guidance of stratification by preeclampsia biomarkers is an important target for future 
research. 
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        5.3 Therapeutic strategies to reduce long-term risk for CVD  
 Both the ACOG93 and the UK NICE94 guidelines include advice for women after pregnancy 
complications associated with increased CVD risk: to keep a healthy weight, engage in increased 
physical activity and refrain from smoking (Supplemental Table 1). The impact of short-term 
prolongation of a severely preeclamptic pregnancy, or of more aggressive antihypertensive therapy 
during pregnancy on the risk for future maternal CVD is uncertain. Also, the independent effect of a 
further pregnancy is not known: either if it is normal or complicated by recurrent preeclampsia. 
Since the early stages of atherosclerosis are reversible it is possible that prompt postpartum 
intervention (for example with statins, metformin, platelet inhibitors/anti-inflammatory drugs such 
as low dose aspirin, angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers) 
could reduce CVD risk. But currently there is no evidence in favor of any intervention whether 
reserved for the highest risk groups or more widely applied.  
 
6. Use of existing pregnancy cohorts and research biobanks  
Collaboration between researchers who have existing pregnancy cohorts and biobanks across the 
world is a necessary prerequisite to solving the problems identified. By prolonging follow-up, using 
standardized protocols and combining data, it should be possible to establish if pregnancy or 
postpartum biomarker measurement can help stratify risk in seemingly healthy parous women 
whose pregnancy outcomes identify them as at risk for CVD. Angiogenic factors measured in 
pregnancy and postpartum79 and related factors should be evaluated as CVD risk assessment tools, 
and “-omics” strategies could be employed to identify new candidate risk or pathophysiological 
factors. Such large datasets, with data collected in a unified way across multiple institutions and 
nations, could be a powerful guide to future intervention trials aimed at reducing the global burden 
of cardiovascular disease. 
6.1 Potential pregnancy biobanks for long-term cardiovascular follow-up 
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 The Global Pregnancy Collaboration (CoLab) (https://pre-empt.cfri.ca/colaboratory) 
includes 30 international member centers, with data from more than 300 000 pregnancies and 
biological materials from 20 000 pregnancies. The goal is to provide conclusive and globally 
generalizable insight into disorders of pregnancy. The CoLab initiative has published 
recommendations for standardizing clinical data and sample collection in studies of 
preeclampsia.95;96 It is also undertaking a pooling of individual measurements of placentally 
associated biomarkers analyzed in 28 different cohorts worldwide.97  
Several of the contributing pregnancy registries and biobanks within the CoLab network are 
undertaking or planning long-term follow-up of maternal disease remote from pregnancy. Data and 
samples have been usually acquired during pregnancy, and only rarely before pregnancy. The Dutch 
Generation R study has followed a large population based cohort of women and their offspring after 
pregnancy.98-100 Another, the Norwegian MoBa study,101;102 including more than 70,000 women and 
100,000 pregnancies also has a long-term follow-up goal. One longitudinal UK study, OxWatch,103  
is studying women from before pregnancy, during pregnancy and beyond. The Preeclampsia 
Registry, developed and managed by the Preeclampsia Foundation and associated with CoLab, is 
accepting participants worldwide, currently enrolling 2,000 women, most of whom have had 
preeclampsia. The database also includes nulliparous and parous sisters, other family members, and 
controls.  
 
7. Harmonization of databases 
The ability to merge the data or samples from different studies is limited by the heterogeneity in 
how and which data are collected, as well as in the frequencies and intervals of clinical follow-up. 
CoLab is developing an online clinical database, originally for prospective studies of preeclampsia, 
which will standardize collection of appropriate data for pregnancy research and will be available 
for general use in 2016. It follows up on previously recommended “minimal and optimal” datasets 
for preeclampsia research,95 and will facilitate pooling of data from such new prospective studies. 
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The principle of harmonization of study data can be extended to all other long-term health outcomes 
after pregnancy, uncomplicated or complicated. Any research study related to human pregnancy 
information (both within and outside the CoLab organization) is encouraged to register their 
pregnancy and/or long-term follow-up research study at an open web platform 
(www.linkregistry.org), to promote research collaboration across studies. 
7.1 An ideal cohort to study remote CVD after pregnancies 
An option, although costly, is to construct a new international, prospective, longitudinal, 
research cohort, which would commence prior to pregnancy, and follow women longitudinally over 
many years to include the “hard endpoints” of CVD (e.g. death, stroke, myocardial infarct). Such a 
cohort should be global in every sense. This “International Longitudinal Women’s Health Cohort” 
will be challenging to fund and administer. Even without such a large formal cohort, we encourage 
that our recommendations of data storage harmonization are adopted for smaller individual studies 
to facilitate study linkages at a later date. 
7.2 “Minimal” and “extended” follow-up research dataset for future CVD after 
pregnancy  
Table 1 summarizes our suggestions for a “minimal” and “extended” research dataset for 
studying long-term cardiovascular health after pregnancy, including suggestions for “cardiovascular 
phenotyping”, collection of general health assessments and pregnancy information. Recruitment 
should not be limited to women at elevated risk for CVD, but also uncomplicated pregnancies. 
Ideally, recruitment should be population based. The suggested follow-up in Table 1 focuses 
specifically on CVD, but could be modified to meet the needs of different health outcomes after 
pregnancy, such as renal, thyroid, neurodegenerative or psychiatric disease. Such studies could 
hopefully identify suitable time points for cost-efficient analyses of the follow-up of (apparently) 
healthy parous women after pregnancy complications.   
In contrast, women in high income countries who have clinical evidence of CVD, either pre-
pregnancy, during pregnancy or postpartum, would be followed up by a specialist (e.g., a 
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cardiologist), with clinical strategies that need individualization and may differ from the suggested 
research oriented suggestion of Table 1. Women with pre-pregnancy diabetes mellitus or renal 
disease should be offered appropriate specialist follow-up postpartum, whatever pregnancy 
complications, to reduce the risk for end-stage organ damage.  
It is important that the data collected and the timing of collection in follow-up studies is 
similar across different studies (Table 1). We suggest that follow-up research studies after 
pregnancy obtain a clinical history, including data on smoking, hypertension and diabetes, obstetric 
history and length of breast feeding from all pregnancies,95 and family history of CVD risk factors. 
In addition we suggest a “minimal” clinical assessment including blood pressure measurement, 
testing for insulin resistance (with fasting blood glucose as a first screening1 or HbA1c or the more 
labor extensive oral glucose testing or HOMA (Homeostasis Model Assessment) score for the 
extended dataset). Our suggested testing for other risk factors for CVD, such as renal disease (urine 
dipstick for proteinuria as a first screening or albumin/creatinine ratio), BMI, total cholesterol, 
LDL-cholesterol, HDL-cholesterol etc., is consistent with CVD risk screening recommended by the 
American Heart Association.1 Table 1 presents a ”minimal dataset” and an “extended dataset” for 
research follow-up.  The ”minimal dataset” is chosen as information that can be collected also in 
low resource setting, in recognition of the necessity of information specific to settings with the 
highest rates of pregnancy complications and deaths from these conditions. 
An “extended” follow-up research plan for CVD includes more detailed cardiovascular 
phenotyping as well as blood sampling for research purposes. Currently, there is no biomarker that 
is known to precisely predict future CVD in young and symptom-free women, who have normal 
kidney function, blood sugar, lipids and blood pressure, therefore adequate samples for various 
analytical options should be collected. Sampling and storage of biological material (blood, placenta, 
possibly urine and feces and other material) would cover a broad range of analytical options and 
biomarker discovery, including options for “-omics” (metabolomics, etc.). 1H NMR metabonomics 
(a form of metabolomics related to nutrition) could for example explore atherosclerotic and CVD 
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pathophysiology.104 Supplemental File 2 details the current most sensible options for extended 
cardiovascular phenotyping in a long-term follow-up clinical research setting, provided the 
necessary skill base is available. Linking imaging and physiologic phenotypes with later health 
outcomes, similar to approaches being used in large scale longitudinal cohorts such as UK 
Biobank,105 may also identify novel vascular or cardiac risk markers that predict which women are 
at greatest risk for later cardiovascular disease.91 Such studies typically use a comprehensive 
approach that captures data on a broad range of cardiovascular parameters, and often include 
assessment of other related systems through metabolic, bone, cerebral or renal imaging and 
assessment. We recognize that many pregnancy-associated research centers may have specialist 
experience or equipment for evaluation of only one, or a few, of these different areas but, through a 
collaborative approach, centers with similar data could be linked to generate combined datasets. In 
addition, there are some non-invasive techniques that do not require major infrastructure and so are 
widely available across multiple sites. Supplemental File 2 considers these common non-invasive 
techniques that could be incorporated into an extended follow-up dataset for research purpose and 
would allow comprehensive assessment across the woman’s macrovasculature (both functional and 
structural investigations), microvasculature and heart.  
7.2.1 Time points for measurement and frequency of postpartum research follow-up 
visits 
The optimal time points for measurements of cardiovascular variables in longitudinal 
follow-up cohorts are unknown. Pre-pregnancy measures will be invaluable to discriminate those 
cardiovascular changes that predispose to pregnancy outcomes as opposed to those developing or 
aggravated by pregnancy itself. However, the challenges of a pre-pregnancy cohort include that 
women do not always plan their pregnancies, nor do pregnancies necessarily occur when planned. 
Thus the time between pre-pregnancy testing and the subsequent pregnancy will vary. Since 
vascular measures change with age, the gap between the time of measurement and the index 
pregnancy may reduce the value of the pre-pregnancy measure. It is not known whether or when in 
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pregnancy vascular phenotyping would be most relevant for unmasking the most reliable risk for 
long-term CVD. Until this question is resolved, testing could ideally be done in early, mid and late 
pregnancy, and, if possible, in the case of preeclampsia when the woman manifests the clinical 
signs. 
The frequency of the suggested clinical research follow-up after pregnancy should be 
standardized to allow determination of the natural history of the progression to cardiovascular 
disease. Potential clinical findings at the follow-up will likely vary between premenopa sal and 
postmenopausal women. Postmenopausal women have a higher short-time CVD risk, with greater 
disease prevalence. On the other hand, identifying increased risk in younger women would be 
optimal to prevent CVD, favoring more frequent and regular examinations of younger and clinically 
healthy women. For harmonizing purposes, we suggest a first 6-12 week postpartum follow-up after 
pregnancy, as this timing is used clinically today as a routine check-up after pregnancy in many 
countries. Thereafter, we suggest a 6 month and 1-year follow-up, with subsequent follow-up at 
least every 5 years for the clinically healthy women. If evidence of clinical CVD is found in this 
research setting, appropriate clinical and specialist follow-up is of course recommended. 
Importantly, even if the resources are not available for such work- intensive follow-up, we strongly 
recommend studies be designed to allow coupling of pregnancy data from the recruited women to 
other potential registries or patient databases documenting clinical (including “hard”) CVD end-
points. 
Several countries currently offer population based health screening programs, such as 
screening for cervical and breast cancer, which are assumed to be cost-effective. However, CVD is 
the greatest cause of death and years of life lost in the world,106 yet no screening is offered due to 
lack of evidence for its efficiency. In order to increase patient compliance and to secure a cost-
efficient follow-up of CVD screening, our suggested “minimal” dataset follow-up could be adapted 
to such pre-existing screening programs, providing added value without much extra cost. This may 
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be a payer issue in countries without government-provided health care, which needs to be taken on 
by professional and consumer organizations as an advocacy initiative.   
 
8. The women’s involvement in long-term follow-up for CVD  
The involvement of women with relevant pregnancy experience in the development of these 
research programs is under-appreciated, but important and enlightening.107 We therefore 
recommend that this research initiative is developed with continuing discussion with appropriate 
patient groups to ensure that their views are fully expressed and incorporated into research 
planning. Patient-run organizations such as, in the US (www.preeclampsia.org), UK (www.action-
on-pre.eclampsia.org.uk) and Australia (www.aapec.org.au) actively support preeclampsia research 
and long-term follow-up for CVD. These organizations have a key role in updating women about 
the evidence for risks of CVD in relation to their pregnancy histories, even though women cannot 
expect routine follow-up without sound evidence that this is beneficial. But, women can strengthen 
the call for more and better research to gain the evidence. They can also help to update health 
personnel who are still relatively unfamiliar with the association of future CVD with pregnancy 
complications.108 They can demand that hospitals provide more and better patient-oriented 
information regarding long-term CVD risk after pregnancy complications (e.g., 
www.themothersprogram.ca). 
 Supporting patient involvement should increase compliance with current (well-meant but 
often ignored) advice on weight control, smoking cessation, and management of additional CVD 
risk factors (e.g., diabetes and hyperlipidemia). The current US93 and UK109 advice on patient-
oriented recommendations is very general. More CVD follow-up research is needed to enable better 
and more specific recommendations.  
  
9. Translation into clinical practice 
We hope that in the future the longitudinal research studies, described here, will be translated into 
widely practiced, evidence-based routines of clinical follow-up, for selected women who have had 
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complicated pregnancies. A suggested template is given in Supplemental Figure 1. Resolution of 
the outstanding research issues that have been identified in this paper could identify which 
biomarkers would help to refine recommendations for,  and timing of, the follow-ups and maximize 
health outcomes cost effectively. This or a similar template could be adapted to differing health 
systems and even linked to other established screening programs, for example those for cervical and 
breast cancer. 
 
 10. Perspectives 
Despite a clearly documented increased risk for cardiovascular disease after pregnancy complicated 
by placental dysfunction or gestational diabetes, our understanding of the underlying mechanisms is 
poor. Nor is it clear how to appropriately target preventive strategies to the women at highest risk 
and what interventions are likely to confer benefit. More long-term research programs are needed 
particularly to discriminate between the specific effects of pregnancy and pre-pregnancy risk factors 
on future maternal CVD.  
 The need for adequately powered, large, longitudinal studies is identified as a critical issue. 
These are expensive and difficult to achieve in isolation. Progress will be faster if data and samples 
are collected in such a way that separate studies can be combined to achieve collaboratively 
determined goals that are otherwise unattainable. This would be powerfully facilitated by pre-
agreed harmonization of research protocols to ensure that important data and samples can be readily 
pooled. We suggest a provisional format for such harmonization and encourage discussion, between 
those involved, to refine its design. In addition, to address the crucial question of the role of pre-
pregnancy risk factors we promote the concept of a new “International Longitudinal Women’s 
Health Cohort”. It should then become possible to validate markers of long-term CVD in young 
women and identify new therapeutic targets for intervention, in collaboration with clinical experts 
on CVD. Better surrogate markers, singly or in combination, for long-term CVD in young women 
will enable targeted testing of primary prophylactic agents many decades prior to the first, and 
possibly lethal, evidence of atherosclerosis and cardiovascular disease.  
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Novelty and significance:  
1) What is new: 
• A template is specified for harmonizing methodologies of follow-up studies after pregnancies, 
complicated by placental dysfunction or gestational diabetes, which aim to determine the 
mechanisms, and quantify the risks, of future cardiovascular disease.  
2) What is relevant: 
• The template will facilitate aggregation of data and biosamples between studies, so enhancing 
their power to increase understanding of all aspects of the evolution of cardiovascular risks after 
abnormal pregnancies. 
3) Summary:  
• More powerful long-term studies, of the relevant early biomarkers, will aid targeting women at 
highest risk of cardiovascular disease for preventive interventions, decades before a lethal event. 
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 AHA(1) ACOG (2) ADA (3) NICE (4, 5) SOMANZ (6) ADIPS (7) 
Preeclampsia, FGR, 
GDM and Premature 
Delivery 
Assessments: 
BP, Lipids, Fasting blood 
glucose, BMI 
Lifestyle advice: 
BMI<25kg/m2 
Healthy diet 
Physical activity  
No smoking 
     
Hypertensive 
Disorder of 
Pregnancy 
  
 
 
 
 
 
 
 Information to women: 
Increased risk of gestational 
hypertension/PE in future 
pregnancy 
Increased risk of 
hypertension and its 
complications later in life 
 
 
 
 
 
 
 
 
  Assessments (yearly if 
preterm PE or recurrent 
PE): BP, Lipids, Fasting 
blood glucose, BMI 
  Assessments: 
BP (yearly) 
Lipids (every 5 years) 
Glucose (every 5 years) 
 
  Lifestyle advice: 
Maintain maternal weight  
 
 
Physical activity 
No smoking 
 Lifestyle advice: 
Maintain maternal weight 
(BMI 18.5-24.9 kg/m2). 
Healthy diet 
 
Lifestyle advice: 
Maintain maternal weight 
 
Healthy diet 
Physical activity 
No smoking 
 
Gestational Diabetes 
Mellitus 
  
 
 
 
 
Assessments: 
OGTT (6 weeks 
postpartum) 
 
 
 
 
 
Assessments: 
Screen for diabetes (6-12 
weeks postpartum and 
every 1-3 years) 
 
Information: 
GDM risk next pregnancy 
Symptoms of 
hyperglycemia 
Assessments: 
Fasting plasma glucose 
before hospital discharge 
Fasting plasma glucose (6-
13 weeks postpartum) 
Test for diabetes when 
planning next pregnancy 
Lifestyle advice: 
Maintain maternal weight 
Healthy diet 
Physical activity 
  
 
 
 
 
Assessments: 
OGTT (6-12 weeks 
postpartum) 
Fasting plasma 
glucose/HbA1C (at 
least every 1-2 
years) 
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Supplemental Table 1 (S1): Examples of current guidelines on clinical follow-up for future cardiovascular disease (CVD) after a pregnancy outcome 
associated with increased CVD risk  
BP: blood pressure; FGR: fetal growth restriction; GDM: gestational diabetes mellitus; OGTT: Oral glucose tolerance test; PE: preeclampsia 
 
1. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of 
cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404-23. 
2. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in 
Pregnancy. Obstet Gynecol. 2013;122(5):1122-31. 
3. Management of diabetes in pregnancy. Diabetes Care. 2015;38 Suppl:S77-9. 
4. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S. Management of hypertensive disorders during 
pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207. 
5. National Institute for Health and Clinical Excellence. Diabetes in pregnancy: management of diabetes and its complications from 
preconception to the postnatal period. 16 Postnatal care. http://www.nice.org.uk/guidance/ng3/chapter/1-recommendations2015. 
6. The SOMANZ Guideline for the Management of Hypertensive Disorders of Pregnancy, (2014). 
7. Nankervis A, MacIntyre HD, Moses R, Ross GP, Callaway L, Porter C, et al. ADIPS Consensus Guidelines for the Testing and Diagnosis 
of Hyperglycaemia in Pregnancy in Australia and New Zealand. 2014. 
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TABLE 1: Harmonization of research studies for future CVD follow-up in low risk young women; suggested "minimal" (green marked)  and "extended" (Itallic) dataset 
VISIT Clinical information Biological samples for research biobanking CV risk phenotyping 
Pregestational Family history of CVD: CVD/CVD death in 1st degree relative, type of CVD, age at time of diagnosis or death
Blood (plasma and serum) and urine 
sampling
BP (blood pressure), measured and reported 
according to accepted guidelines
Basics (Physical, anthropological and ethnographic data): 
Age, height and weight (BMI) and waist/hip ratio
Blood screen for: Dyslipidemia (total cholesterol, LDL-
cholesterol, HDL-cholesterol) and Diabetes Mellitus 
(fasting blood glucose or HbA1c)
Smoking history (never, irregularly, regularly use, current 
use): Cigarette/Cigar or snuff or chews tobacco/nicotine Urine screen: protein (and hematuria/ glucosuria)
Medical history : Hypertension, cardiac disease, stroke, 
renal disease, pregestational DM (type and treatment), 
collagen vascular disease, systemic lupus erythematosus, 
obstructive sleep apneaObstetric history (gravidity, parity: indicate numbers and 
gestational age at deliveries): Miscarriage, stillbirth, abortions 
(induced/spontaneous), Pregnancy induced hypertension, 
preeclampsia, eclampsia, HELLP, Small for gestational 
age/Fetal growth restriction, Gestational DM (treatment type), 
preterm delivery (<37 weeks), neonatal death, placental 
weights
Self-described ethnicity (White, Black, Asian, Hispanic, 
unknown, or other [mixed])
Cardiovascular phenotyping 1: Macrovasculature 
Function (Endothelial function and Arterial stiffness) 
and Structure (Carotid imaging)
Years of schooling/other  socioeconomic indicator Cardiovascular phenotyping 2 : Microvasculature (rarefaction) 
Maternal/paternal (and grandparent) country of birth Cardiovascular phenotyping 3:  Echocardiography
Physical activity (IPAQ) and Diet questionnaires Oral glucose tolerance test (OGT)/ HOMA score 
Breast feeding history (duration and after how many 
pregnancies?)
Pregnancies (all trimesters 
preferrably) Updated Family history of CVD, basics, smoking, medical/ 
obstetric history (as in pregestational visit above)
Longitudi nal blood (plasma and 
serum) and urine sampling, according 
to Myatt et al, Hypertension 2014
BP, measured and reported according to accepted 
guidelines (see S1 references for pregnancy BP) 
Pregnancy clinical information, including maternal/fetal 
outcome and placenta variables (ref Myatt al,  Hypertension 
2014)
Placental sampling,  according to 
Burton et al, Placenta 2014
Urine screen: protein (and hematuria/glucosuria and 
UTI screen). Albumin/creatinine ratio (longitudinal, 
until positive diagnosis of proteniuria/preeclampsia)
OGT/ HOMA score 
US registrations from pregnancy: Uteroplacental Doppler 
blood flow findings and fetal growth measurements Cardiovascular phenotyping:1-3 (as above)
Postpartum (6-12 weeks, 6 
months and 1 year after 
index pregnancy,  then 
every 5th year)
Update of family history of CVD, basics, smoking, medical 
/ obstetric history (as in pregestational visit above)
Blood (plasma and serum) and urine 
sampling BP, measured and reported according to accepted 
guidelines
Physical activity (IPAQ) and Diet questionnaires Urine screen: protein (and hematuria/ glucosuria)
Breast feeding history (duration)
Blood screen for: Dyslipidemia (total cholesterol, LDL-
cholesterol, HDL-cholesterol) and Diabetes Mellitus 
(fasting blood glucose or HbA1c)
Oral glucose tolerance test (3-6 months postpartum 
after GDM is recommended clinically)
Cardiovascular phenotyping:1-3 (as above)
